Have a feature idea you'd love to see implemented?
Let us know!
BVS Bioventus Inc
Price (delayed)
$13.28
Market cap
$1.08B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.65
Enterprise value
$1.43B
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations
Highlights
The gross profit has grown by 11% YoY and by 4.2% from the previous quarter
The gross margin rose by 6% year-on-year
The company's net income has shrunk by 94% QoQ but it has surged by 85% YoY
Bioventus's EPS has plunged by 91% from the previous quarter but it has soared by 86% YoY
Bioventus's equity has decreased by 18% YoY and by 12% from the previous quarter
The quick ratio has declined by 16% since the previous quarter and by 12% year-on-year
Key stats
What are the main financial stats of BVS
Market
Valuations
Earnings
Shares outstanding
80.97M
Market cap
$1.08B
Enterprise value
$1.43B
Price to earnings (P/E)
N/A
Price to book (P/B)
7
Price to sales (P/S)
1.58
EV/EBIT
N/A
EV/EBITDA
32.96
EV/Sales
2.66
Revenue
$536.89M
EBIT
-$7.89M
EBITDA
$43.28M
Free cash flow
$8.44M
Per share
Balance sheet
Liquidity
EPS
-$0.65
Free cash flow per share
$0.13
Book value per share
$1.9
Revenue per share
$8.38
TBVPS
$5.62
Total assets
$792.17M
Total liabilities
$603.11M
Debt
$383.28M
Equity
$150.94M
Working capital
$77.42M
Debt to equity
2.54
Current ratio
1.33
Quick ratio
0.73
Net debt/EBITDA
8.12
Margins
Efficiency
Dividend
EBITDA margin
8.1%
Gross margin
66.5%
Net margin
-7.8%
Operating margin
-11.2%
Return on assets
-5.2%
Return on equity
-24.9%
Return on invested capital
-1.6%
Return on capital employed
-1.4%
Return on sales
-1.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BVS stock price
How has the Bioventus stock price performed over time
Intraday
2.39%
1 week
2.79%
1 month
16.9%
1 year
321.59%
YTD
151.99%
QTD
11.13%
Financial performance
How have Bioventus's revenue and profit performed over time
Revenue
$536.89M
Gross profit
$357.17M
Operating income
-$60.34M
Net income
-$41.96M
Gross margin
66.5%
Net margin
-7.8%
The operating income has plunged by 139% from the previous quarter but it has soared by 77% YoY
Bioventus's operating margin has shrunk by 133% QoQ but it has surged by 79% YoY
The company's net income has shrunk by 94% QoQ but it has surged by 85% YoY
BVS's net margin has shrunk by 90% QoQ but it has soared by 86% YoY
Growth
What is Bioventus's growth rate over time
Valuation
What is Bioventus stock price valuation
P/E
N/A
P/B
7
P/S
1.58
EV/EBIT
N/A
EV/EBITDA
32.96
EV/Sales
2.66
Bioventus's EPS has plunged by 91% from the previous quarter but it has soared by 86% YoY
BVS's price to book (P/B) is 197% more than its last 4 quarters average of 2.3
Bioventus's equity has decreased by 18% YoY and by 12% from the previous quarter
BVS's P/S is 158% above its last 4 quarters average of 0.6
The revenue is up by 5% year-on-year and by 2.7% since the previous quarter
Efficiency
How efficient is Bioventus business performance
The return on invested capital has dropped by 139% since the previous quarter but it has surged by 97% year-on-year
Bioventus's ROS has plunged by 138% from the previous quarter but it has soared by 97% YoY
The ROE has dropped by 102% since the previous quarter but it has soared by 77% year-on-year
The return on assets has dropped by 93% since the previous quarter but it has surged by 79% year-on-year
Dividends
What is BVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BVS.
Financial health
How did Bioventus financials performed over time
Bioventus's total assets is 31% more than its total liabilities
The quick ratio has declined by 16% since the previous quarter and by 12% year-on-year
BVS's current ratio is down by 13% since the previous quarter and by 9% year-on-year
BVS's debt is 154% higher than its equity
BVS's debt to equity is up by 20% year-on-year and by 11% since the previous quarter
Bioventus's equity has decreased by 18% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.